Widera, Paweł
Welsing, Paco M. J.
Ladel, Christoph
Loughlin, John
Lafeber, Floris P. F. J.
Petit Dop, Florence
Larkin, Jonathan
Weinans, Harrie
Mobasheri, Ali
Bacardit, Jaume
Article History
Received: 25 October 2019
Accepted: 20 April 2020
First Online: 21 May 2020
Competing interests
: Florence Petit Dop is employee of Servier. Jonathan Larkin is employee and stockholder at GlaxoSmithKline. Christoph Ladel is employee of Merck. All other authors declare no potential conflict of interest.